MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer  by Cekaite, Lina et al.
MiR-9, -31, and -182 Deregulation
Promote Proliferation and Tumor
Cell Survival in Colon Cancer1,2
Lina Cekaite*,†, Juha K. Rantala‡, Jarle Bruun*,†,
Marianne Guriby*,†, Trude H. Ågesen*,†,
Stine A. Danielsen*,†, Guro E. Lind*,†,
Arild Nesbakken†,§, Olli Kallioniemi¶,#,
Ragnhild A. Lothe*,†,3 and Rolf I. Skotheim*,†,3
*Department of Cancer Prevention, Institute for Cancer
Research, Norwegian Radium Hospital, Oslo University
Hospital, Oslo, Norway; †Centre for Cancer Biomedicine,
Faculty of Medicine, University of Oslo, Oslo, Norway;
‡Knight Cancer Institute, Oregon Health and Science
University, Portland, OR; §Department of Gastrointestinal
Surgery, Oslo University Hospital, Aker, Oslo, Norway;
¶Institute for Molecular Medicine Finland, Helsinki, Finland;
#Medical Biotechnology, VTT Technical Research Centre
of Finland, Turku, Finland
Abstract
Several microRNAs (miRNAs) are known to be deregulated in colon cancer, but the mechanisms behind their potential
involvement on proliferation and tumor cell survival are unclear. The present study aimed to identify miRNAs with func-
tional implications for development of colon cancer. The cell proliferation and apoptosis were examined following per-
turbations of miRNA levels by employing a comprehensive miRNA library screen. miRNAs nominated for relevance
to colon cancer were validated on expression and functional levels. By integrating the effect of miRNA up-regulation
with the endogenous miRNA expression levels within the HT29, HCT116, and SW480 colon cancer cell lines, we iden-
tified miRNAs controlling cell proliferation (n=53) and apoptosis (n=93). From these functionally nominatedmiRNAs,
we narrowed the list to 10 oncogene- and 20 tumor suppressor–like miRNAs that were also differentially expressed
between colon cancer (n = 80) and normal colonic mucosa (n = 20). The differential expressions of miR-9, miR-31,
and miR-182 were successfully validated in a series of colon carcinomas (n = 30) and polyps (n = 10) versus normal
colonic mucosa (n = 10), whereas the functional effect was confirmed in an in-depth validation using different cell
viability and apoptotic markers. Several transcription factors and genes regulating cell proliferation were identified as
putative target genes by integrative miRNA/mRNA expression analysis obtained from the same colon cancer patient
samples. This study suggests that deregulated expression of miR-9, miR-31, and miR-182 during carcinogenesis plays
a significant role in the development of colon cancer by promoting proliferation and tumor cell survival.
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Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related
death worldwide [1]. It is a complex genetic disease caused by abnor-
malities in gene structure and/or expression [2]. An aberrant expression
of endogenous small noncoding regulatory RNAs (∼22 nt) called
microRNA (miRNA) has been reported in multiple human cancer types,
including cancers of the lung, breast, brain, liver, leukemia, and CRC
[3]. The deregulated expression of certain miRNAs has been found
to correlate with prognosis and therapeutic outcome in patients with
CRC and suggested as promising prognostic biomarkers, found in blood
and feces from patients with CRC [4–6].
The involvement of oncogenes and tumor suppressor genes in the
control of cell proliferation and survival pathways is well established
for protein-coding genes [7,8]. However, with about half of the pro-
tein coding mRNAs being subjected to miRNA-mediated regula-
tion, miRNAs’ role as important regulators of cancer critical genes
is firmly established [9]. In normal tissue, miRNA-induced regulation
contributes to maintain a normal state of cell growth, proliferation,
differentiation, and apoptosis. The deregulation of miRNAs’ expres-
sion leads to abnormal activity of miRNA target genes. For instance,
overexpression of an oncogenic miRNA may cause excessive repres-
sion of a target tumor suppressor gene, and conversely, silencing of
a tumor-suppressive miRNA may give ectopic levels of a target onco-
protein. Consequently, deregulation of certain miRNAs may result
in cells with selective advantages such as increased proliferation or
survival [10]. Because individual miRNAs can regulate multiple tar-
gets, it should be stressed that their function may differ between cell
types, depending on which of their target genes are being expressed.
Although several miRNAs have been reported as deregulated in CRC,
correlated with poor patient prognosis, suggested as cancer biomarkers,
or otherwise implicated in cancer development, little is known about
their biologic function. A large-scale investigation of miRNAs is there-
fore warranted to improve the understanding of miRNA functions
and their regulatory networks. Understanding the function of miRNAs
may provide new insights into cancer development and offer novel
potential biomarkers and therapeutic targets.
Materials and Methods
Cell Lines
The colon cell lines HCT116, HT29, and SW480 were obtained
from American Type Culture Collection and cultured according to
their recommendations. Authentication of the cell lines was done
by using the AmpFlSTR Identifiler PCR Amplification Kit (Applied
Biosystems, Carlsbad, CA; March 2011).
Patient Samples
The miRNA expression data set Colon cancer series I, published
by Sarver et al. [11], was downloaded from The National Center for
Biotechnology Information’s (NCBI’s) Gene Expression Omnibus
(GEO; accession number GSE18392).
The in-house validation series, Colon cancer series II, consisted of
fresh frozen primary colon cancer samples consecutively collected at
the University Hospital of Oslo (Aker, Norway) between 2005 and
2008. A summary of clinical data is presented in Table W1. In 10 of
the patients, polyps and corresponding normal colonic mucosa were
taken from visually disease-free areas. Tumors were staged according
to the American Joint Cancer Committee/Union for International
Cancer Control (AJCC/UICC). Microsatellite stable/microsatellite
instability (MSS/MSI) status was obtained from Berg et al. [12].
Written informed consent was obtained from all subjects included.
The research biobank has been registered according to national legisla-
tion and the study has been approved by the Regional Committee for
Medical Research Ethics, South-Eastern Norway (Biobank 2781; REK
South-East S-09282c2009/4958).
miRNA Functional Library Screen
The proliferative and apoptotic potential of miRNA gain of func-
tions was considered by use of the cell spot microarray (CSMA)
technology as previously described [13]. Briefly, HCT116, HT29, and
SW480 cells were transfected on CSMAs composed of four technical
replicates of a human pre-miR miRNA Precursor Library v2 (Ambion
at Life Technologies Inc, Paisley, UK) containing 319 chemically
modified double-stranded RNA molecules designed to mimic endo-
genous mature human miRNAs. After 48-hour knock-in transfection,
cells were fixed and stained for fluorescence microscopic analysis of cell
proliferation and induction of apoptosis. The proliferative effect was
measured by the 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay
(Invitrogen at Life Technologies Inc, Paisley, UK). The effect of miRNA
overexpression on apoptosis was measured by immunocytochemistry
detection of the apoptosis marker cleaved ADP-ribose polymerase
(cPARP; Cell Signaling Technology, Danvers, MA, MAb #9546). The
arrays were imaged and analyzed with an Olympus scanR (Olympus,
Munich, Germany) automated high-content imager to detect the
nuclear EdU and cPARP signals in comparison to DNA counter-
staining (4′,6-diamidino-2-phenylindole) of the cells. Z -score values
calculated in comparison to the mean signal ratios and SDs across all
samples were used to identify miRNAs inducing significant EdU or
cPARP signal changes.
According to the recommendations for high-throughput siRNA
screens of the RNAi Global Informatics Work Group, we have made
available raw data from the colon cancer miRNA functional screen,
prepared in the MIARE format (Table W2).
miRNA Expression in Colon Cancer Cell Lines
Total RNA containing small RNA was extracted from cell pellets
using the TRIzol Reagent (Invitrogen by Life Technologies, Carlsbad,
CA) according to the manufacturer’s recommendations. The quantity
and quality of the RNA were determined using the NanoDrop (Thermo
Fisher Scientific, Waltham, MA) and BioAnalyzer (Agilent Technolo-
gies, Santa Clara, CA), respectively. miRNA expression profiling in
colon cancer cell lines was performed by using GeneChip miRNA
Array (Affymetrix, Santa Clara, CA) according to the manufacturer’s
protocol. The Robust Multi-array Analysis method was employed for
background correction, normalization, and probe summarization using
the Partek genomic suite software (Partek Inc., St Louis, MO). Raw data
have been deposited in GEO (accession number GSE35946).
Identification of Differentially Expressed miRNA in Colon
Cancers from a Publicly Available Data Set
Colon cancer series I processed data, according to Sarver et al. [11],
were imported into R (version 2.11). The differential expression of
miRNAs in colon cancer versus normal colonic mucosa was obtained
using Significance Analysis of Microarrays with a Wilcoxon rank sta-
tistic in siggene package (version 1.24) in Bioconductor (version 2.7)
[14]. miRNA expression in colon cancer altered by ≥15% with false
discovery rate (FDR)-corrected P value ≤ .001 compared to normal
colonic mucosa was considered as differentially expressed.
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Validation of Differential miRNA Expression in an
In-house Series of Colon Cancers by Quantitative
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from fresh frozen colon cancer, polyps,
and normal mucosa (Colon cancer series II, Table W1) by using the
miRNeasy kit (Qiagen, Hilden, Germany), according to the manufac-
turer’s instructions. The quantity and quality of the RNA were deter-
mined as previously described. Six hundred nanograms of total RNA
was used to synthesize cDNA with the TaqMan MicroRNA Reverse
Transcription (RT) Kit (Applied Biosystems, Foster City, CA) and
Megaplex RT Primers (Applied Biosystems) following the manufac-
turer’s protocol. The polymerase chain reaction (PCR) mix consisted
of 10 ng of template cDNA, 0.5 μl of 20× TaqMan MicroRNA Assay
(Applied Biosystems), 2× TaqMan Universal Master Mix II without
UNG (Applied Biosystems), and RNase-free water to a total volume
of 10 μl. Real-time PCR was performed with 7900HT Fast Real-Time
PCR system (Applied Biosystems) according to the manufacturer’s
instructions. Human U6 snRNA was used as reference.
Functional Validation
The HCT116 cell line was reverse transfected with the miRNA in-
hibitors anti–miR-31 and anti–miR-182 and the miRNA mimics pre–
miR-9 and pre–miR-139-5p (all from Applied Biosystems) at 100 nM
using X-tremeGENE siRNA Transfection Reagent (Roche, Mannheim,
Germany) 48 hours before assaying the cells. Anti-/pre-miR negative
controls were included. Cell viability and cytotoxicity were simulta-
neously measured on the basis of live- and dead-cell protease activity;
apoptosis was measured by caspase-3/7 activity. All parameters were
analyzed within a single well using the ApoTox-Glo Triplex Assay
(Promega, Madison, WI) according to the manufacturer’s instructions.
Validation of Knock-in and Knock-down of miRNA
Expression by Quantitative RT-PCR
RNA from the transfected HCT116 cells was obtained by follow-
ing the protocol of the TaqMan MicroRNA Cells-to-Ct Kit (Applied
Biosystems). cDNA synthesis and real-time PCR were performed with
specific assays for the four miRNAs and reference human U6 snRNA
(all TaqMan MicroRNA assays, Applied Biosystems).
miRNA Target Analysis
The integration of miRNA and mRNA expression data in the same
colon cancer patient samples (Colon cancer series II) was performed
using the Partek software, using TargetScan v5.2 and MicroCosm
Targets v5 miRNA target prediction databases. In-house–generated
genome-wide mRNA expression data were obtained using GeneChip
Human Exon 1.0 ST Arrays (Affymetrix), previously deposited to GEO
(accession numbers GSE24550 and GSE29638) [15,16]. Spearman
rank correlation was calculated to determine mRNAs that are negatively
correlated to miRNA expression.
Results
Following perturbations of miRNA levels in colon cancer cell lines,
we examined cell proliferation and apoptosis alongside with the cell
lines’ endogenous miRNA expression. miRNAs nominated for rele-
vance to colon cancer were validated on expression and functional
levels. Figure 1 presents a flowchart of the study design.
Functional Screening for miRNAs that Regulate Proliferation
and Apoptosis of Colon Cancer Cells
To analyze whether miRNAs may act as regulators of cell prolifera-
tion and/or apoptosis in colon cancer, we employed the miniaturized
CSMA method [13], which facilitated the transfection of a precursor
library of 319 human miRNAs in three colon cancer cell lines. The
large-scale screen of miRNAs permitted an independent evaluation of
up-regulation of each individual miRNA. The overexpression of the
majority of miRNAs had no effect on proliferation or on apoptosis,
and these results were independent of their endogenous expression
level within the cell lines. Nevertheless, overexpression of a subset of
miRNAs resulted in increased or decreased proliferation (Figure 2A)
and increased or decreased apoptosis (Figure 2B). For an miRNA to
be considered oncogene-like in the particular colon cancer cell line,
we required that it is significantly expressed and stimulated cell prolif-
eration and/or repress apoptosis upon up-regulation. A threshold higher
than the 70th percentile of the expression intensities was employed to
discriminate reliably expressed oncogene-like miRNAs with prolifera-
tive and/or survival advantage. Similarly, expression below a threshold
at the 70th percentile was employed to nominate tumor suppressor–
like miRNAs with concomitantly reduced proliferation and/or in-
creased apoptosis. The effects of 1 SD below and 1 SD above the mean
signal ratios on proliferation and apoptosis markers were considered.
Oncogene and Tumor Suppressor–like miRNAs
A total of 53 and 93 miRNAs were scored as oncogene- and tumor
suppressor–like miRNAs in at least one cancer cell line, respectively.
From the oncogene-like miRNAs, 24 miRNAs increased proliferation,
32 miRNAs reduced apoptosis, and 3 miRNAs exerted both effects
(Figure 3A). From the nominated tumor suppressor–like miRNAs,
54 miRNAs were associated with decreased proliferation, 58 with
induced apoptosis, and 19 miRNAs exerted both effects (Figure 3B).
The most potent pro-proliferative effect was seen for miR-181b in
the HT29 cell line (Figure 2A), increasing cell proliferation more than
four times. The most potent antiapoptotic miRNAs included miR-182,
miR-15b, and miR-21 (Figure 2B). To investigate whether the iden-
tified oncogene or tumor suppressor–like miRNAs were involved in
development of colon cancer, we made use of an external publicly avail-
able miRNA expression data set (Colon cancer series I) of 80 colon
cancer and 28 normal colonic mucosa samples [11]. This showed that
19% of the identified oncogene- and 22% of the tumor suppressor–like
miRNAs were differentially expressed in colon cancer compared to
normal colonic mucosa (Figure 3).
Among oncogene-like miRNAs, miR-31 and miR-182 were more
than two-fold overexpressed, whereas tumor suppressor–like miRNAs
miR-9, miR-1, and miR-139-5p were found more than two-fold down-
regulated in colon cancers compared to normal colonic mucosa. Inter-
estingly, although miR-181b was found differentially expressed only
for a subset of the colon cancers, the expression correlated positively
with the patients’ clinical stage (r = 0.36, P = .002) and showed signifi-
cantly increased expression in cancers from stage IV patients.
Expression Validation of the Selected Hits
Seven miRNAs were selected for expression validation in an inde-
pendent series of colon cancers. Six of these were identified from the
functional screen as oncogene-like (miR-31,miR-182, andmiR-210) or
tumor suppressor–like (miR-9, miR-139-5p, and miR-10b), and all
were differentially expressed in colon cancer versus normal colonic
mucosa in the data set of Sarver et al. [11]. In addition, oncogene-like
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Figure 1. Study design. A functional screen of cell lines was followed by assessment of the positive hits from miRNA expression data
from cell lines and colon cancer patients in a publicly available data set. Further, the best candidates were validated by qRT-PCR in an
independent in-house series of clinical samples and functionally validated by up-regulation of tumor suppressor– and down-regulation of
oncogene-like miRNAs. The putative target genes of validated miRNAs were identified by employing miRNA and mRNA expression
obtained from the same colon cancer patient samples and two miRNA target prediction databases.
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miR-21, which showed no differential expression in the external data
set and, however, was reported overexpressed in multiple previous
studies, was also included. Quantitative RT-PCR (qRT-PCR) was
employed to measure expression levels from 30 colon cancer samples
of all clinical stages, and 10 matched normal colonic mucosa samples
as well as 10 polyps from patients with colon cancer (Colon cancer
series II, Table W1).
From the qRT-PCR analysis, the expression of three of the four
oncogene-like miRNAs, miR-31, miR-182, and miR-21, was found
increased in colon cancers across all clinical stages, as well as polyps,
compared to normal colonic mucosa (Figures 4 andW1). Furthermore,
the expression of miR-31 and miR-21 correlated with disease stage
(Table W3). None of the validated oncogene-like miRNAs were sig-
nificantly associated with MSI/MSS phenotypes.
The expression of the two tumor suppressor–like miRNAs, miR-9
and miR-139-5p, was found decreased in colon cancers across all clini-
cal stages, as well as polyps, compared to normal colonic mucosa (Fig-
ures 4 and W1). Down-regulation of miR-10b in colon cancer was
not confirmed in the clinical validation cohort across all stages; how-
ever, we found weak expression of miR-10b in stage I cancers (Figures 4
and W1).
For both oncogene- and tumor suppressor–like miRNAs, analysis of
the paired samples showed similar results as the group-wise analyses
(Figure W2).
Functional Validation
To confirm the miRNA library screening results, we performed
in-depth validation of the four miRNAs that passed all initial screening
and follow-up analyses as being relevant to colon cancer. We upregu-
lated the tumor suppressor–like miRNAs, miR-9 and miR-139-5p,
which were endogenously expressed at low levels. Conversely, we
downregulated the oncogene-like miRNAs, miR-31 and miR-182,
which were endogenously expressed at high levels. To ascertain that
we obtained the optimal up-regulation or knock-down of the miRNAs,
we first controlled the transfections by measuring miRNA expression
levels by qRT-PCR (Figure 5, A and B). The repression of miR-31
and miR-182 in the HCT116 cell line resulted in 12% and 22%
increased apoptosis, respectively (Figure 5C ), confirming the already
identified antiapoptotic effect of miR-31 and miR-182. Of note,
the effect on apoptosis was measured on caspase-3/7 activity, which
is different from the marker detecting apoptosis used in the func-
tional miRNA library screening, thus strengthening the validation.
We also concluded that the repression of miR-31 and miR-182 led
to reduced cell viability, but the oligos did not induce cytotoxicity
(Figure 5E ). When the tumor suppressor–like miRNAs, miR-9 and
miR-139-5p, were upregulated, we observed 40% increase in apoptosis
in miR-9–transfected cells but no effect upon miR-139-5p transfec-
tions (Figure 5D).
Altogether, the functional data demonstrated that miR-9, miR-31,
and miR-182 had an effect on apoptosis, confirming the effect detected
in the miRNA library screen.
Integrative Analysis of miRNA/mRNA Expression Identifies
Putative Target Genes
To further analyze the role of the miRNAs in gene regulation in
colon cancer, we investigated putative target genes by employing
miRNA and mRNA expression data obtained from the same colon
cancer patient samples (Colon cancer series II) and two miRNA target
Figure 3. Comparison of functionally nominated and differentially expressed miRNAs in colon cancer. Venn diagrams illustrated the relation-
ships between miRNAs that modulate proliferation and apoptosis, identified as significantly differentially expressed between colon cancer
versus normal colonic mucosa. The associations for oncogene-like and tumor suppressor–like miRNAs are presented in A and B, respectively.
Neoplasia Vol. 14, No. 9, 2012 Functional miRNA Screen in Colon Cancer Cekaite et al. 873
874 Functional miRNA Screen in Colon Cancer Cekaite et al. Neoplasia Vol. 14, No. 9, 2012
prediction databases. These integrative analyses revealed significant
inverse correlation of several genes that were predicted to have binding
site for miR-9, miR-31, or miR-182 (Figure 6). Of particular interest,
eight transcription factors, CEBPA, SCML4, SATB2, AGT, FOXF2,
PSRC1, HOXD1, and NR2E1, and five genes that involved regulation
of cell proliferation, CEBPA, FGFR3, AGT, IL13, and NR2E1, were
among those that were negatively correlated.
Discussion
miRNAs regulate complex networks of gene expression, and altered
expression of miRNA genes has been associated with development
of multiple human cancer types, including CRC [3]. However, the
function of the deregulated miRNA expression is not well under-
stood. Here, we have employed a comprehensive miRNA library screen
measuring cell proliferation and apoptosis to search for functional
miRNAs in colon cancer, which comprises the majority of CRC cases
[1]. Among oncogene (pro-proliferative, antiapoptotic) and tumor
suppressor (antiproliferative, proapoptotic)–like miRNAs identified in
the present study, about one-fifth of each type were found differentially
expressed in colon cancer compared to normal colonic mucosa. By
integrating the functional effect of miRNA expression up-regulation
with the endogenous miRNA expression, we were able to identify
oncogene- and tumor suppressor–like miRNAs. Importantly, miRNA
expression profiling of colon cancer cell lines showed that relatively
few of the miRNAs were profoundly expressed, in agreement with
the assumption of tissue specificity of the miRNA expression [17].
Thus, miRNAs that have been demonstrated as oncogenes or tumor
suppressors in other types of cancers may not be relevant to colon can-
cer because of absent expression in both cancerous and normal colonic
tissues. The integration of endogenous miRNA expression allowed us
to focus on colon cancer–specific miRNAs. Furthermore, the iden-
tified hits were subjected to further selection based on the differential
expression in colon cancer versus normal colonic mucosa in a publicly
available data set and additionally validated in an independent
in-house series of patients with colon cancer. This additional clinical
validation step was critical, because the existing published data on miRNA
expression in CRC report only partly overlapping profiles [6,11,18].
In the present study, the up-regulation of already highly expressed
miR-31 in colon cancer cell lines resulted in reduced apoptosis. Fur-
thermore, a high expression level of miR-31 in polyps indicated that
the augmentation of miR-31 expression occurred in early premalignant
development. This is in agreement with a report by Olaru et al., who
examined miR-31 expression in patients with inflammatory bowel
disease (IBD) and showed that miR-31 expression increased stepwise
during progression from IBD to IBD-related neoplasia and accurately
discriminated IBD-related neoplasias from normal or chronically in-
flamed tissues in patients with IBD [19]. There have also been several
reports showing differential expression of miR-31 between MSS and
MSI carcinomas [11,20]. This trend was also seen in our data but
did not reach statistical significance. MiR-31 was the most upregu-
lated one among the identified miRNAs, and its increased expression
resulted in reduced apoptosis in HT29 cancer cells. Even though
the effect on apoptosis in HCT116 cell line was not obvious in
the miRNA library screen, the more sensitive, subsequent in-depth
functional validation revealed increased apoptosis when miR-31 was
downregulated. In agreement with our results, it has been shown
that suppression of miR-31 increases sensitivity to 5-fluorouracil in
HCT116 cells and reduces cell migration and invasion [21]. Our find-
ings on oncogenic abilities of miR-31 corroborates well with previous
studies that reported increased expression level of miR-31 associated
with the progression of CRC and deeper invasion of CRC tumors
[22–25]. However, a downregulated expression of miR-31 has been
reported in breast, prostate, and ovarian cancers [26,27]. Interestingly,
although miR-31 overexpression in a number of ovarian cancer cell
lines with a dysfunctional TP53 pathway inhibited proliferation and
induced apoptosis [27], the overexpression of miR-31 in colon cancer
cell line HT29, carrying TP53 mutation, resulted in a high anti-
apoptotic effect, whereas the antiapoptotic effect of the miR-31 over-
expression was lower or absent in HCT116 and SW480, which have
a functional TP53 pathway. This is in agreement with the observa-
tion of Creighton et al. in ovarian cancer cell lines. Taken together, it
seems that not only the expression but also the functions of miR-31 are
cancer specific and likely cell context dependent.
To our knowledge, the current study is the first to report a link
between high expression of miR-182 and reduced apoptosis in colon
cancer. This was clearly seen for two independent cell lines, revealing
miR-182 as the most potent apoptotic miRNA in the present study.
The overexpression of miR-182 in colon cancer reported by Sarver
et al. [11] was validated in the independent in-house sample series of
colon carcinomas and also found in precursor lesions. The deregula-
tion of the miR-182 has been described in several other cancer types
[28–30]. Previously, we have reported chromosomal aberrations
that differentiate the clinical stages of CRC, as well as those that
are responsible for the progression into liver metastases, by perform-
ing a meta-analysis of data obtained from comparative genomic
hybridization studies [31]. Interestingly, the miR-182 gene, a com-
ponent of the miRNA cluster miR-183-96-182 located in the 7q32
genomic region, was found amplified in 26% of primary tumors
and 30% of liver metastases, suggesting that miR-182 stimulates
CRC progression by increasing the cell survival. Given that the
liver is the most common target organ for metastases of CRC [32],
and the small oligonucleotides tend to accumulate in the liver for
clearance [33], anti–miR-182 therapy may have a potential in the
treatment of metastatic colon cancer. Recently, the efficient down-
regulation of miR-182 has been demonstrated to decrease melanoma
liver metastasis and tumor burden in mice [34].
Figure 4. Relative miRNA expression levels in colon cancer tissue and normal colonic mucosa in two independent colon cancer patient
series. (A) Oncogene-like miRNA expression and (B) tumor suppressor–like miRNA expression were determined by miRNA microarrays
in the Colon cancer series I (colon cancers, n = 80; normal colonic mucosa, n = 28) and validated by qRT-PCR in Colon cancer series II
(colon cancers, n= 30; normal colonic mucosa, n= 10; polyps, n= 10). The fold change is given for colon cancer versus normal colonic
mucosa (or polyp vs normal colonic mucosa). The box plots summarize all analyzed patients, where the top and bottom of the box
represent the upper and lower quartiles, and the line in the middle represents the median. The whiskers (lines extending above and
below the boxes) represent the highest and lowest values that are not regarded outliers or extreme values. Outliers (values that are
between 1.5 and 3 times the interquartile range) and extreme values (values that are more than 3 times the interquartile range) are
represented by circles and stars beyond the whiskers.
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The tumor suppressor–like miRNA, miR-9, identified by the
functional screening, was only expressed at very low levels in the
colon cancer cell lines and found downregulated in the first colon
cancer series. Its downregulated expression was validated in an in-
dependent colon cancer series and functional validation confirmed
the proapoptotic effect of miR-9, and its up-regulation resulted in
decreased cell viability. In agreement with our results, deregulated
miR-9 expression has also been reported in several other cancer types
[35–38]. The mature sequence of miR-9 is produced by three genes
in the human genome, miR-9-1, miR-9-2, and miR-9-3, encoded at
Figure 5. Functional validation of the selected miRNAs. Relative expression of the miRNAs after (A) knock-down of oncogene-like
miRNAs by transfection of anti-miRs and (B) up-regulation of tumor suppressor–like miRNAs after transfection of miRNA mimics
(pre-miRs) compared to expression levels in negative controls. Increased apoptosis was measured by caspase-3/7 activity 48 hours after
transfection and following (C) down-regulation of oncogene-like and (D) up-regulation of tumor suppressor–like miRNAs. Effect on cyto-
toxicity and cell viability was measured by protease activities 48 hours after (E) down-regulation of oncogene-like and (F) up-regulation of
tumor suppressor–like miRNAs.
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chromosomes 1, 5, and 15, respectively. MiR-9-1 and miR-9-3 have
a CpG island in the region, whereas miR-9-2 does not. The meth-
ylation of the miR-9-1 CpG island was frequently observed in CRC
cell lines and in primary CRC tumors and was associated with the
presence of lymph node metastases [39]. We have previously reported
that the chromosomal band 5q14.3, among others encoding miR-9-2,
was lost in 10% of polyps, 14% of primary tumors, and 22% of liver
metastases, whereas the band 15q26.1, encoding miR-9-3 gene, was
lost in 13% of primary tumors and 17% of liver metastases [31].
Unexpectedly, miR-9-1 gene mapping to the chromosomal band
1q22 was gained in 9% of primary tumors and in 16% of liver metas-
tases. So far, the relation between deregulation of miR-9 expression
and tumorigenesis is not well understood. Here, we present the first
evidence of direct miR-9 involvement in the regulation of cell prolifer-
ation and apoptosis in colon cancer. Interestingly, the reduction of
miR-9 expression was identified in polyps and within all stages of
colon cancer. However, the lowest expression of miR-9 was found at
the earliest clinical stages, suggesting that miR-9 is important in the
initiation and early development of colon cancer. However, it is impor-
tant to point out that miR-9 function is not limited to the repression of
proliferation and apoptosis. Ma et al. [40] demonstrated that miR-9-3
expression was activated by MYC/MYCN and resulted in repression
of E-cadherin, leading to increased cell motility and invasiveness and
formation of cancer metastasis in breast cancer. Furthermore, miR-9
levels were raised in primary tumors from breast cancer patients with
metastases compared with metastasis-free patients [41]. The role of
miR-9 in metastasis development in colon cancer still needs to be
elucidated. However, the elevated levels of miR-9 expression seen in
late clinical stages indicate that miR-9 is involved in multiple steps of
colon cancer development, from initiation to metastasis. It is tempting
to speculate that the reactivation of miR-9 expression could occur
through gain of 1q22 locus and/or positive transcriptional regulation
by MYC/MYCN.
It is unlikely that miRNAs will be responsible for a specific tumor
phenotype by repressing a single target gene. We demonstrate by
using the integrative analyses of miRNA and mRNA expression data
obtained from the same colon cancer patient samples that the herein
identified oncogene- and tumor suppressor–like miRNAs have several
putative mRNA target genes that are involved in the regulation of
transcription and proliferation. Of particular interest, the miR-9 target
gene and transcription factor, NR2E1 (nuclear receptor subfamily 2
group E member 1, also known as nuclear receptor TLX), has been
reported as essential for neural stem cell proliferation, and disruption
of its expression led to significant induction of p21 and PTEN gene
expression and to dramatic inhibition of neural stem cell proliferation
[42], whereas the putative target of miR-182, FOXF2 (forkhead tran-
scription factor 2), encodes the so-called mesenchymal factors that
control epithelial proliferation and survival and links hedgehog to
Figure 6. Heat map of putative target gene expression. Expression of negatively correlated (Spearman rank correlation, P value < .05)
predicted target genes to (A) oncogene-like miRNAs, miR-31 and miR-182, and (B) tumor suppressor–like miRNA, miR-9. Each row
represents a single gene, and each column represents a colon cancer patient sample. The degree of color saturation corresponds to
the ratio of gene expression in each sample compared to the mean expression across all samples (log2 scale). The cancer samples are
sorted by miRNA expression as illustrated in triangles above each heat map.
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BMP andWNT signaling [43]. Interestingly, the putative target genes of
the identified miRNAs were enriched within gene sets that we have pre-
viously reported as deregulated pathways in CRC [44]. Importantly, and
in contrast to targeting of single genes, miRNA-based cancer gene ther-
apy offers the possibility of targeting multiple genes and networks and
forms the theoretic basis of correcting the tumor phenotype through tar-
geting causative oncogenic pathways.
To conclude, this paper presents a novel integrative approach of
identifying miRNAs in colon cancer by implementing a dual cell pro-
liferation and apoptosis functional screen and miRNA expression pro-
filing. By follow-up with integration of a publicly available miRNA
expression data set and ultimately a clinical miRNA expression valida-
tion in an in-house patient series, we have evaluated the miRNAs likely
to play roles as oncogenes or tumor suppressors. MiR-9, miR-31, and
miR-182 were identified and validated as implicated in cell proliferation
and apoptosis in colon cancer.
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Figure W1. Relative miRNA expression levels in colon cancer tissue and normal colonic mucosa in validation series II, as determined
by qRT-PCR. The fold change is given as colon cancer versus normal colonic mucosa; the box plots summarize all analyzed colon
cancers (n = 30). The tumor stage is based on the TNM stage criteria of AJCC/UICC. MSS/MSI status was obtained as described in
Materials and Methods.
Table W1. Summary of Clinicopathologic and Molecular Characteristics of Validation Series.
Characteristics Counts
Patients
Age at diagnosis
Average 64.2
Range 42–73
Gender
Female 13
Male 17
Tissue samples
Colon cancer 30
Polyp 10
Normal colonic mucosa 10
Tumors
Stage*
TNM1 5
TNM2 11
TNM3 9
TNM4 5
MSS/MSI status
MSI 6
MSS 24
*Stage—tumors were staged according to the AJCC/UICC; normal colonic mucosa samples were
taken from visually disease-free areas of patients with colon cancer.
Table W3. Correlation between miRNA Expression in Colon Cancer Patients and Their Clinicopathologic and Molecular Characteristics.
miR-21 miR-31 miR-182 miR-210 miR-9 miR-10b miR-139-5p
Tissue type (normal versus polyp, colon cancer) 0.62* 0.59* 0.66* −0.22 −0.53* −0.12 −0.64*
Stage 0.40† 0.37† 0.19 0.34 0.50* 0.33 0.21
MSS/MSI −0.08 0.23 0.05 0.36† 0.01 0.19 −0.19
Gender 0.35 0.19 0.24 0.11 0.45† 0.09 0.24
*Pearson correlation is significant at the 0.01 level (two-tailed).
†Pearson correlation is significant at the 0.05 level (two-tailed).
Figure W2. Hierarchical clustering of relative miRNA expression levels within 10 matched triplets of colon cancer, polyps, and normal
colonic mucosa samples. The log2 fold change is given for colon cancer versus normal colonic mucosa and polyp versus normal colonic
mucosa, whereas normal colonic mucosa samples were normalized to the mean.
